Psoriasis is an immune disease caused by rapid and incomplete differentiation of skin basal cells. Natural products such as indirubin have historically served as excellent sources for the treatments of psoriasis. However, the poor solubility and bioavailability due to its plane and rigid crystal structure, which limits its efficacy. Herein, to improve the efficacy of indirubin, a hydrogel-based microemulsion drug delivery system was developed for transdermal delivery. The mean droplet size of the optimized microemulsion was 84.37 nm, with a polydispersity index (PDI) less than 0.2 and zeta potential value of 0~-20 mV. The transdermal flux and skin retention of indirubin at 24 h were 47.34 ± 3.59 μg/cm 2 and 8.77 ± 1.26 μg/cm 2 , respectively. The optimized microemulsion was dispersed in carbomer 934 hydrogel to increase the consistency. The indirubin-loaded microemulsion gel was tested on an imiquimod-induced psoriasis mouse model. Results showed that this preparation can improve psoriasis symptoms by down-regulating the expression of IL-17A, Ki67, and CD4 + T. This experiment provides great scalability for researchers to treat psoriasis, avoid first-pass effects, and increase the concentration of targeted drugs.
Keyphrases
- wound healing
- drug delivery
- crystal structure
- mouse model
- atopic dermatitis
- cancer therapy
- hyaluronic acid
- induced apoptosis
- rheumatoid arthritis
- poor prognosis
- high glucose
- photodynamic therapy
- squamous cell carcinoma
- radiation therapy
- depressive symptoms
- physical activity
- cell cycle arrest
- drinking water
- endothelial cells
- neoadjuvant chemotherapy
- mass spectrometry
- oxidative stress
- signaling pathway
- endoplasmic reticulum stress
- simultaneous determination
- long non coding rna
- climate change
- tissue engineering
- high resolution
- liquid chromatography
- pi k akt
- sensitive detection
- rectal cancer